Tempus AI: 15min RSI Oversold, KDJ Golden Cross

In a recent analysis of Tempus AI's 15-minute chart, several key indicators were noted. Firstly, the Relative Strength Index (RSI) reached oversold levels, suggesting that the stock price had experienced a rapid decline and was likely due for a rebound. Furthermore, the KDJ Golden Cross was triggered at 08/26/2025 09:45, indicating a shift in momentum from a downward trend to an upward one. This suggests that the stock price has the potential to continue its upward trajectory and may experience further increases in value.

In a recent development, Tempus AI, Inc. (NASDAQ:TEM) has made significant strides in its strategic acquisitions and financial performance. The company's purchase of Paige, a leading AI-driven pathology company, marks a pivotal move in the race to dominate the $10 billion oncology AI market by 2030 [2]. This acquisition has not only expanded Tempus' dataset to include 7 million digitized pathology slides but also provided FDA-cleared tools to enhance its AI capabilities. The combined dataset, totaling 350 petabytes of clinical data, creates an unmatched asset for unbiased AI models and drug discovery.

Tempus AI's Q2 2025 revenue surged 89.6% year-over-year to $314.6 million, with a significant increase in genomics revenue to $241.8 million. The company's data and services segment, which includes AI-driven insights for biotech firms, also grew by 35.7% year-over-year to $72.8 million. This robust financial performance underscores Tempus' ability to monetize its data and AI capabilities while maintaining profitability.

Furthermore, Tempus AI's recent stock-based acquisition of Paige preserves cash and ensures smooth operations through the integration of Microsoft Azure cloud services. The company's balance sheet remains strong, with a $750 million convertible note issuance providing flexibility for future AI initiatives without diluting shareholder value.

From a technical perspective, a recent analysis of Tempus AI's 15-minute chart reveals several key indicators. The Relative Strength Index (RSI) reached oversold levels, suggesting a potential rebound in the stock price after a rapid decline. Additionally, the KDJ Golden Cross was triggered on August 26, 2025, at 09:45, indicating a shift in momentum from a downward trend to an upward one. These indicators suggest that Tempus AI's stock price has the potential to continue its upward trajectory and may experience further increases in value.

Institutional investors have also shown interest in Tempus AI, with several new positions being established in the first quarter. HSBC Holdings PLC, Cliffwater LLC, Cladis Investment Advisory LLC, Partners Group Holding AG, Tyler Stone Wealth Management, and United Capital Management of KS Inc. have all purchased new shares in Tempus AI, collectively representing 24.22% of the stock held by institutional investors [1].

In summary, Tempus AI's strategic acquisition of Paige, combined with strong financial performance and positive technical indicators, positions the company as a leader in AI-driven precision medicine. Investors should closely monitor Tempus AI's future developments and financial reports to assess the potential for further growth.

References:
[1] https://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-purchases-new-shares-in-tempus-ai-inc-tem-2025-08-26/
[2] https://www.ainvest.com/news/tempus-ai-strategic-acquisition-paige-catalyst-dominance-ai-driven-oncology-2508/